Thursday, July 31, 2014 1:53:33 PM
You are not the bank manager to whom Kim is applying for a loan.
You are not the director of the company.
You are at best a minor stockholder, and you don't deserve, nor are you allowed to demand, any special consideration or inside information.
KBLB's stock is offered for sale on the open market.
You may buy it if you wish at your own risk, and sell it as and when you desire.
You have the right to buy the stock.
You have the right to sell the stock.
Those are your rights.
In addition, because KBLB has chosen to be a fully reporting company, you get a lot of financial information as reported to the SEC, and KBLB and its officers are required not to make false and misleading statements.
They are required to state that certain forward looking statements are only guesses and should not be relied upon.
They are not required to make any statements whatsoever except that they are required to publicly report to the SEC any major significant change to their financials or that would impact future financials.
Because of its low PPS KBLB tends to get compared to many OTC penny stocks, but unlike many of these KBLB being fully reporting must be very circumspect in its PRs and filings and general.
Scam stocks can tell you everything you want to know and all sorts of details.
his is done to make their lies more believable.
Luckily Kim T. does not need to employ those tactics.
Mike L.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM